Patients with the disease are denoted as such given a genetic expression profile resembling Ph+ ALL; however, no BCR-ABL1 fusion gene is observed in this high-risk subtype defined by genetic changes leading to aberrant kinase signaling [46]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.